BioArctic AB will present at Jefferies 2018 London Healthcare Conference on November 15, at 4.40 p.m. local time (GMT).
Stockholm, Sweden, November 13, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present at Jefferies 2018 London Healthcare Conference on November 15, at 4.40 p.m. local time (GMT).
BioArctic is a research-based biopharmaceutical company focusing on disease modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a treatment for complete spinal cord injury. The company focuses on new types of treatments in areas with high unmet medical needs. BioArctic was founded in 2003 based on innovative research from Uppsala University, Sweden.
The company has cutting-edge scientific competence and experience in developing drugs from idea to market. Collaborations with universities are of great importance to the company together with the strategically important global partners in the Alzheimer and Parkinson projects. BioArctic conducts its own clinical development in the field of complete spinal cord injury. Through long-term collaboration agreements with global pharmaceutical companies, BioArctic has demonstrated high skills and great ability to deliver innovative pharmaceutical projects.
In Alzheimer’s disease, BioArctic has collaborated with Eisai since 2005. The company has entered into three research agreements and two license agreements relating to the antibodies BAN2401 and BAN2401 back-up. In July 2018, BioArctic reported positive topline 18 months results of the BAN2401 Phase 2b study in 856 early Alzheimer’s patients. Eisai is currently discussing the next steps for BAN2401 with regulatory authorities and preparing for further clinical studies.
In Parkinson’s disease, BioArctic has collaborated with AbbVie since 2016, when a research collaboration agreement was entered including i.a. the antibody BAN0805. BioArctic announced earlier this month that AbbVie exercised its option to license BioArctic’s portfolio of antibodies targeting alpha-synuclein for Parkinson’s disease, pending clearance under the U.S. antitrust legislation. BAN0805 is in preparation for an IND-application to start the first clinical study in the U.S. next year.
In complete spinal cord injury, BioArctic’s project SC0806 is in clinical Phase 1/2.
For more information, please contact
Christina Astrén, IR & Communications Director, BioArctic AB
E-mail: christina.astren@bioarctic.se
Telephone: + 46 70 835 43 36
This information was submitted for publication at 08:00 a.m. CET on November 13, 2018.
About BioArctic
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.
BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com
